Additionally, biomarkers of amyloid and tau do not always accurately predict the extent of cognitive impairment, with some cognitively impaired individuals exhibiting normal amyloid levels, and 30% to 40% of cognitively unimpaired elderly individuals showing AD pathology.1, 22. This evidence concerns the gene MAPT and Alzheimer disease.